Abstract:Abstract Background Acral melanoma (AM) is the most common subtype in Chinese melanoma patients with a very poor prognosis. However, our understanding of the disease pathogenesis and molecular landscape is limited by the few studies that have been conducted. Here, we profiled the clinical characteristics, mutational landscapes and tumor immune microenvironment of AM patients to gain insights into disease characteristics and potential treatment strategies. Methods A total of 90 AM patients were enrolled and their tissue samples were subjected to next-generation sequencing and multiplexed immunohistochemistry tests. Kaplan–Meier curves and log-rank tests were used to analyze the prognostic potential of various genetic aberrations and immune cell compositions in AM. Results The median disease-free survival was 21.3 months and estimated median overall survival (OS) was 60 months. More advanced stages, older ages and thickness of greater than 4 mm were associated with worse prognosis in AM patients (HR = 2.57, 95% CI 1.25–5.29, p = 0.01; HR = 2.77, 95% CI 1.22–6.28, p = 0.02; HR = 3.43, 95% CI 1.51–7.82, p < 0.01, respectively), while patients who received post-surgical treatments had better survival (HR = 0.36, 95% CI 0.17–0.76, p = 0.01). The most frequently altered genes included BRAF (14.5%), KIT (16.9%), NRAS (12%), NF1 (10.8%), APC (7.2%), and ARID2 (6%). Copy number variations (CNV) were commonly found in CCND1 (19.3%), CDK4 (19.3%), MDM2 (14.5%) and FGF19 (12%). CDK4 amplifications was independently associated with shorter OS in AM patients (HR = 3.61, 95% CI 1.38–9.46, p = 0.01). CD8 + T cells (p < 0.001) and M1 macrophages (p = 0.05) were more highly enriched in the invasive margin than in the tumor center. Patients with higher levels of M1 macrophage infiltration in the invasive margin derived markedly longer OS (HR = 0.43, 95% CI 0.20–0.95, p = 0.03). Interestingly, in CDK4-amplified patients, there tended to be a low level of M1 macrophage infiltration in the invasive margin (p = 0.06), which likely explains the poor prognosis in such patients. Conclusions Our study provided a comprehensive portrait of the clinicopathological features, genetic aberrations and tumor microenvironment profiles in AM patients and identified candidate prognostic factors, which may facilitate development of additional therapeutic options and better inform clinical management of AM patients. Based on these prognostic factors, further studies should focus on enhancing the infiltration of M1 macrophages, especially in CDK4-amplified AM patients.

Gene Expression Screening Identifies CDCA5 As a Potential Therapeutic Target in Acral Melanoma.

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Prognostic Value of Genetic Aberrations and Tumor Immune Microenvironment in Primary Acral Melanoma

Delineating the Early Dissemination Mechanisms of Acral Melanoma by Integrating Single-Cell and Spatial Transcriptomic Analyses

Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments

Establishment of a CD8+ T cells-related prognostic risk model for acral melanoma based on single-cell and bulk RNA sequencing

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Prevalent Aberrations of CDK4 Pathway in Acral Melanoma and Implications for Targeted Therapy.

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations

Frequency of CDK2 , CCNE1 Copy Number Variation in Acral Melanoma and Implications for CDK Inhibitor in Targeted Therapy

Whole Genome and RNA Sequencing Reveal the Distinct Genomic Landscape of Acral Melanoma.

Genetic Aberrations in the CDK4 Pathway and Association with Innate Resistance to PD-1 Blockade in Acral Melanoma.

Long Non-Coding RNA Expression Identified by Microarray Analysis: Candidate Biomarkers in Human Acral Lentiginous Melanoma

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment

A single-cell atlas reveals tumor heterogeneity and immune environment of acral melanoma

High G2 and S-phase Expressed 1 Expression Promotes Acral Melanoma Progression and Correlates with Poor Clinical Prognosis.

Molecular Cluster Mining of Adrenocortical Carcinoma Via Multi-Omics Data Analysis Aids Precise Clinical Therapy.

Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin